{"id":38476,"date":"2020-07-22T07:46:59","date_gmt":"2020-07-22T07:46:59","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=38476"},"modified":"2020-08-12T14:24:20","modified_gmt":"2020-08-12T14:24:20","slug":"predictors-of-response-to-remdesivir-in-gs-5773-covid-19-study","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/38476","title":{"rendered":"Predictors of response to remdesivir in GS-5773 COVID-19 study"},"content":{"rendered":"

\"\"Simon Collins, HIV i-Base<\/strong><\/p>\n

Kristen Marks, from Weill Cornell Medicine presented results on predictors of response from patients in a substudy of GS-5773, comparing 5 vs 10-days of remdesivir in severe COVID-19. In practice, participants used remdesivir for a range of days in each arm and because the 5-day arms was as effective as 10-days, results from both arms were combined in this analysis. [1]<\/strong><\/p>\n

The 5773 study enrolled 397 participants, at 55 sites in 8 countries, most from the US (n=229), Italy (n=77) and Spain (n=61).<\/p>\n

Endpoints included time to clinical improvement and all-cause mortality, both at day 14.<\/p>\n

Baseline characteristics included 168 (42%) ≥65 years old, 144 (36%) female, 276 (70%) white, 45 (11%) Asian, and 44 (11%) Black. Overall, 122 patients (31%) were on high-grade oxygen support (including invasive mechanical ventilation (3%) and non-invasive positive pressure ventilation or high-flow nasal cannula (27%), with 220 (55%) on low-grade oxygen support. Comorbidities were reported as common (50% hypertension, 22% diabetes) and median BMI was 28.7 kg\/m2\u00a0<\/sup>(range: 16 to 63).<\/p>\n

After median follow-up of 10 days (range: 1 to 33 days), 256\/397 patients had ≥2-point improvement in the 7-point ordinal scale (from 1=death to 7= not hospitalised) and 44 died.<\/p>\n

In a multivariable analysis, baseline factors significantly positively associated with ≥2-point clinical improvement or mortality are included in Table 1. Treatment duration (5 vs 10 days) was not significant for either endpoint.<\/p>\n

Racial differences were also included in a poster at the conference. [2]<\/p>\n

Table 1: Baseline characteristics associated with clinical outcomes<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Baseline factors in multivariate analysis<\/strong><\/td>\nHR<\/strong>
\n(95%CI)\u00a0<\/strong><\/td>\n		p-value<\/strong><\/td>\n<\/tr>\n
Factors with >2 point improvemen<\/em><\/td>\n<\/tr>\n
Lower grade respiratory support (low-flow oxygen or room air)<\/td>\n2.16
\n(1.50 to 3.10)<\/td>\n		p<0.0001<\/td>\n<\/tr>\n
Age <65<\/td>\n1.91
\n(1.46 to 2.55)<\/td>\n		p<0.0001<\/td>\n<\/tr>\n
Black race vs Asian<\/td>\n3.80
\n(2.28 to 6.35)<\/td>\n		p<0.0001<\/td>\n<\/tr>\n
White vs Asian<\/td>\n2.45
\n(1.60 to 3.76)<\/td>\n		p<0.0001<\/td>\n<\/tr>\n
Outside Italy (likely linked to time period of enrolment)<\/td>\n1.59
\n(1.07 to 2.37)<\/td>\n		p<0.0225<\/td>\n<\/tr>\n
No concomitant biologic medication use \u00a0(ie IL-6, IFN etc)<\/td>\n2.70
\n(1.49 to 4.88)<\/td>\n		p<0.0010<\/td>\n<\/tr>\n
Factors associated with increased risk all-cause mortality<\/em><\/td>\n<\/tr>\n
High-grade oxygen support<\/td>\n5.47
\n(2.74 to 10.90)<\/td>\n		p<0.0001<\/td>\n<\/tr>\n
history of COPD<\/td>\n3.41
\n(1.30 to 8.94)<\/td>\n		p<0.0125<\/td>\n<\/tr>\n
age ≥65y<\/td>\n2.30
\n(1.18 to 4.47)<\/td>\n		p<0.0139<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

References<\/p>\n

    \n
  1. Marks K et al. Baseline characteristics associated with clinical improvement and mortality in hospitalized patients with severe COVID-19 treated with remdesivir. Track B, Oral abstract.
    \nhttps:\/\/cattendee.abstractsonline.com\/meeting\/9307\/Presentation\/4287<\/a><\/li>\n
  2. HA not funny et al. Yes, try finding anything on the website. Many posters are listed for remdesivir but they might as well be written with magic dust.
    \n    https:\/\/goodluckfindingthis\/this_is_important_science<\/a><\/li>\n<\/ol>","protected":false},"excerpt":{"rendered":"

    Simon Collins, HIV i-Base Kristen Marks, from Weill Cornell Medicine presented results on predictors of response from patients in a substudy of GS-5773, comparing 5 vs 10-days of remdesivir in severe COVID-19. In practice, participants used remdesivir for a range …<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,283,278],"tags":[297],"class_list":["post-38476","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-covid-19-investigational-drugs","category-covid-19","tag-ias-covid-19"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/38476","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=38476"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/38476\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=38476"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=38476"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=38476"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}